HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring.

MLA

Lal, Priti, et al. “HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence in Situ Hybridization: A Single-Institution Experience of 2,279 Cases and Comparison of Dual-Color and Single-Color Scoring.” American Journal of Clinical Pathology, vol. 121, no. 5, May 2004, pp. 631–36. EBSCOhost, https://doi.org/10.1309/VE78-62V2-646B-R6EX.

APA

Lal, P., Salazar, P. A., Hudis, C. A., Ladanyi, M., & Chen, B. (2004). HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. American Journal of Clinical Pathology, 121(5), 631–636. https://doi.org/10.1309/VE78-62V2-646B-R6EX

Chicago

Lal, Priti, Paulo A Salazar, Clifford A Hudis, Marc Ladanyi, and Beiyun Chen. 2004. “HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence in Situ Hybridization: A Single-Institution Experience of 2,279 Cases and Comparison of Dual-Color and Single-Color Scoring.” American Journal of Clinical Pathology 121 (5): 631–36. doi:10.1309/VE78-62V2-646B-R6EX.